81 FR 87047 - Current List of HHS-Certified Laboratories and Instrumented Initial Testing Facilities Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Substance Abuse and Mental Health Services Administration Federal Register Volume 81, Issue 232 (December 2, 2016)
Substance Abuse and Mental Health Services Administration
Federal Register Volume 81, Issue 232 (December 2, 2016)
| Page Range | 87047-87049 | |
| FR Document | 2016-28940 |
[Federal Register Volume 81, Number 232 (Friday, December 2, 2016)] [Notices] [Pages 87047-87049] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2016-28940] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Current List of HHS-Certified Laboratories and Instrumented Initial Testing Facilities Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies AGENCY: Substance Abuse and Mental Health Services Administration, HHS. ACTION: Notice. ----------------------------------------------------------------------- SUMMARY: The Department of Health and Human Services (HHS) notifies federal agencies of the laboratories and Instrumented Initial Testing Facilities (IITF) currently certified to meet the standards of the Mandatory Guidelines for Federal Workplace Drug Testing Programs (Mandatory Guidelines). The Mandatory Guidelines were first published in the Federal Register on April 11, 1988 (53 FR 11970), and subsequently revised in the Federal Register on June 9, 1994 (59 FR 29908); September 30, 1997 (62 FR 51118); April 13, 2004 (69 FR 19644); November [[Page 87048]] 25, 2008 (73 FR 71858); December 10, 2008 (73 FR 75122); and on April 30, 2010 (75 FR 22809). A notice listing all currently HHS-certified laboratories and IITFs is published in the Federal Register during the first week of each month. If any laboratory or IITF certification is suspended or revoked, the laboratory or IITF will be omitted from subsequent lists until such time as it is restored to full certification under the Mandatory Guidelines. If any laboratory or IITF has withdrawn from the HHS National Laboratory Certification Program (NLCP) during the past month, it will be listed at the end and will be omitted from the monthly listing thereafter. This notice is also available on the Internet at http://www.samhsa.gov/workplace. FOR FURTHER INFORMATION CONTACT: Giselle Hersh, Division of Workplace Programs, SAMHSA/CSAP, 5600 Fishers Lane, Room 16N03A, Rockville, Maryland 20857; 240-276-2600 (voice). SUPPLEMENTARY INFORMATION: The Mandatory Guidelines were initially developed in accordance with Executive Order 12564 and section 503 of Public Law 100-71. The ``Mandatory Guidelines for Federal Workplace Drug Testing Programs,'' as amended in the revisions listed above, requires strict standards that laboratories and IITFs must meet in order to conduct drug and specimen validity tests on urine specimens for federal agencies. To become certified, an applicant laboratory or IITF must undergo three rounds of performance testing plus an on-site inspection. To maintain that certification, a laboratory or IITF must participate in a quarterly performance testing program plus undergo periodic, on-site inspections. Laboratories and IITFs in the applicant stage of certification are not to be considered as meeting the minimum requirements described in the HHS Mandatory Guidelines. A HHS-certified laboratory or IITF must have its letter of certification from HHS/SAMHSA (formerly: HHS/NIDA), which attests that it has met minimum standards. In accordance with the Mandatory Guidelines dated November 25, 2008 (73 FR 71858), the following HHS-certified laboratories and IITFs meet the minimum standards to conduct drug and specimen validity tests on urine specimens: HHS-Certified Instrumented Initial Testing Facilities Dynacare, 6628 50th Street NW., Edmonton, AB Canada T6B 2N7, 780-784- 1190, (Formerly: Gamma-Dynacare Medical Laboratories) HHS-Certified Laboratories ACM Medical Laboratory, Inc., 160 Elmgrove Park, Rochester, NY 14624, 844-486-9226 Aegis Analytical Laboratories, Inc., 345 Hill Ave., Nashville, TN 37210, 615-255-2400 (Formerly: Aegis Sciences Corporation, Aegis Analytical Laboratories, Inc., Aegis Analytical Laboratories) Alere Toxicology Services, 1111 Newton St., Gretna, LA 70053, 504-361- 8989/800-433-3823 (Formerly: Kroll Laboratory Specialists, Inc., Laboratory Specialists, Inc.) Alere Toxicology Services, 450 Southlake Blvd., Richmond, VA 23236, 804-378-9130 (Formerly: Kroll Laboratory Specialists, Inc., Scientific Testing Laboratories, Inc.; Kroll Scientific Testing Laboratories, Inc.) Baptist Medical Center-Toxicology Laboratory, 11401 I-30, Little Rock, AR 72209-7056, 501-202-2783 (Formerly: Forensic Toxicology Laboratory Baptist Medical Center) Clinical Reference Laboratory, Inc., 8433 Quivira Road, Lenexa, KS 66215-2802, 800-445-6917 DrugScan, Inc., 200 Precision Road, Suite 200, Horsham, PA 19044, 800- 235-4890 Dynacare,* 245 Pall Mall Street, London, ONT, Canada N6A 1P4, 519-679- 1630 (Formerly: Gamma-Dynacare Medical Laboratories) --------------------------------------------------------------------------- * The Standards Council of Canada (SCC) voted to end its Laboratory Accreditation Program for Substance Abuse (LAPSA) effective May 12, 1998. Laboratories certified through that program were accredited to conduct forensic urine drug testing as required by U.S. Department of Transportation (DOT) regulations. As of that date, the certification of those accredited Canadian laboratories will continue under DOT authority. The responsibility for conducting quarterly performance testing plus periodic on-site inspections of those LAPSA-accredited laboratories was transferred to the U.S. HHS, with the HHS' NLCP contractor continuing to have an active role in the performance testing and laboratory inspection processes. Other Canadian laboratories wishing to be considered for the NLCP may apply directly to the NLCP contractor just as U.S. laboratories do. Upon finding a Canadian laboratory to be qualified, HHS will recommend that DOT certify the laboratory (Federal Register, July 16, 1996) as meeting the minimum standards of the Mandatory Guidelines published in the Federal Register on April 30, 2010 (75 FR 22809). After receiving DOT certification, the laboratory will be included in the monthly list of HHS-certified laboratories and participate in the NLCP certification maintenance program. --------------------------------------------------------------------------- ElSohly Laboratories, Inc., 5 Industrial Park Drive, Oxford, MS 38655, 662-236-2609 Fortes Laboratories, Inc., 25749 SW Canyon Creek Road, Suite 600, Wilsonville, OR 97070, 503-486-1023 Laboratory Corporation of America Holdings, 7207 N. Gessner Road, Houston, TX 77040, 713-856-8288/800-800-2387 Laboratory Corporation of America Holdings, 69 First Ave., Raritan, NJ 08869, 908-526-2400/800-437-4986 (Formerly: Roche Biomedical Laboratories, Inc.) Laboratory Corporation of America Holdings, 1904 Alexander Drive, Research Triangle Park, NC 27709, 919-572-6900/800-833-3984 (Formerly: LabCorp Occupational Testing Services, Inc., CompuChem Laboratories, Inc.; CompuChem Laboratories, Inc., A Subsidiary of Roche Biomedical Laboratory; Roche CompuChem Laboratories, Inc., A Member of the Roche Group) Laboratory Corporation of America Holdings, 1120 Main Street, Southaven, MS 38671, 866-827-8042/800-233-6339 (Formerly: LabCorp Occupational Testing Services, Inc.; MedExpress/National Laboratory Center) LabOne, Inc. d/b/a Quest Diagnostics, 10101 Renner Blvd., Lenexa, KS 66219, 913-888-3927/800-873-8845 (Formerly: Quest Diagnostics Incorporated; LabOne, Inc.; Center for Laboratory Services, a Division of LabOne, Inc.) MedTox Laboratories, Inc., 402 W. County Road D, St. Paul, MN 55112, 651-636-7466/800-832-3244 MetroLab-Legacy Laboratory Services, 1225 NE 2nd Ave., Portland, OR 97232, 503-413-5295/800-950-5295 Minneapolis Veterans Affairs Medical Center, Forensic Toxicology Laboratory, 1 Veterans Drive, Minneapolis, MN 55417, 612-725-2088, Testing for Veterans Affairs (VA) Employees Only National Toxicology Laboratories, Inc., 1100 California Ave., Bakersfield, CA 93304, 661-322-4250/800-350-3515 One Source Toxicology Laboratory, Inc., 1213 Genoa-Red Bluff, Pasadena, TX 77504, 888-747-3774 (Formerly: University of Texas Medical Branch, Clinical Chemistry Division; UTMB Pathology-Toxicology Laboratory) Pacific Toxicology Laboratories, 9348 DeSoto Ave., Chatsworth, CA 91311, 800-328-6942 (Formerly: Centinela Hospital Airport Toxicology Laboratory) Pathology Associates Medical Laboratories, 110 West Cliff Dr., Spokane, WA 99204, 509-755-8991/800-541-7891x7 Phamatech, Inc., 15175 Innovation Drive, San Diego, CA 92128, 888-635- 5840 Quest Diagnostics Incorporated, 1777 Montreal Circle, Tucker, GA 30084, [[Page 87049]] 800-729-6432 (Formerly: SmithKline Beecham Clinical Laboratories; SmithKline Bio-Science Laboratories) Quest Diagnostics Incorporated, 400 Egypt Road, Norristown, PA 19403, 610-631-4600/877-642-2216 (Formerly: SmithKline Beecham Clinical Laboratories; SmithKline Bio-Science Laboratories) Quest Diagnostics Incorporated, 8401 Fallbrook Ave., West Hills, CA 91304, 818-737-6370 (Formerly: SmithKline Beecham Clinical Laboratories) Redwood Toxicology Laboratory, 3700 Westwind Blvd., Santa Rosa, CA 95403, 800-255-2159 Southwest Laboratories, 4625 E. Cotton Center Boulevard, Suite 177, Phoenix, AZ 85040, 602-438-8507/800-279-0027 STERLING Reference Laboratories, 2617 East L Street, Tacoma, Washington 98421, 800-442-0438 US Army Forensic Toxicology Drug Testing Laboratory, 2490 Wilson St., Fort George G. Meade, MD 20755-5235, 301-677-7085, Testing for Department of Defense (DoD) Employees Only Charles LoDico, Chemist. [FR Doc. 2016-28940 Filed 12-1-16; 8:45 am] BILLING CODE 4160-20-P
![Federal Register / Vol. 81, No. 232 / Friday, December 2, 2016 / Notices 87047
person may petition FDA for a This notice is being published less than 15 Boulevard, Bethesda, MD 20892 (Telephone
determination regarding whether the days prior to the meeting due to the timing Conference Call).
applicant for extension acted with due limitations imposed by the review and Contact Person: Najma Begum, Ph.D.,
funding cycle. Scientific Review Officer, Review Branch,
diligence during the regulatory review
(Catalogue of Federal Domestic Assistance DEA, NIDDK, National Institutes of Health,
period. To meet its burden, the petition Room 7349, 6707 Democracy Boulevard,
Program Nos. 93.853, Clinical Research
must be timely (see DATES) and contain Bethesda, MD 20892–5452, (301) 594–8894,
Related to Neurological Disorders; 93.854,
sufficient facts to merit an FDA Biological Basis Research in the begumn@niddk.nih.gov.
investigation. (See H. Rept. 857, part 1, Neurosciences, National Institutes of Health, Name of Committee: National Institute of
98th Cong., 2d sess., pp. 41–42, 1984.) HHS) Diabetes and Digestive and Kidney Diseases
Petitions should be in the format Special Emphasis Panel; PAR–16–034:
Dated: November 28, 2016.
specified in 21 CFR 10.30. NIDDK Ancillary Studies (R01).
Submit petitions electronically to Sylvia L. Neal, Date: February 6, 2017.
http://www.regulations.gov at Docket Program Analyst, Office of Federal Advisory Time: 11:00 a.m. to 1:00 p.m.
No. FDA–2013–S–0610. Submit written Committee Policy. Agenda: To review and evaluate grant
petitions (two copies are required) to the [FR Doc. 2016–28902 Filed 12–1–16; 8:45 am] applications.
Place: National Institutes of Health, Two
Division of Dockets Management (HFA– BILLING CODE 4140–01–P
Democracy Plaza, 6707 Democracy
305), Food and Drug Administration, Boulevard, Bethesda, MD 20892 (Telephone
5630 Fishers Lane, Rm. 1061, Rockville, Conference Call).
MD 20852. DEPARTMENT OF HEALTH AND Contact Person: Najma Begum, Ph.D.,
HUMAN SERVICES Scientific Review Officer, Review Branch,
Dated: November 28, 2016.
DEA, NIDDK, National Institutes of Health,
Leslie Kux, National Institutes of Health Room 7349, 6707 Democracy Boulevard,
Associate Commissioner for Policy. Bethesda, MD 20892–5452, (301) 594–8894,
[FR Doc. 2016–28939 Filed 12–1–16; 8:45 am] National Institute of Diabetes and begumn@niddk.nih.gov.
BILLING CODE 4164–01–P
Digestive and Kidney Diseases; Notice (Catalogue of Federal Domestic Assistance
of Closed Meetings Program Nos. 93.847, Diabetes,
Pursuant to section 10(d) of the Endocrinology and Metabolic Research;
DEPARTMENT OF HEALTH AND Federal Advisory Committee Act, as 93.848, Digestive Diseases and Nutrition
HUMAN SERVICES Research; 93.849, Kidney Diseases, Urology
amended (5 U.S.C. App.), notice is and Hematology Research, National Institutes
National Institutes of Health hereby given of the following meetings. of Health, HHS)
The meetings will be closed to the
public in accordance with the Dated: November 28, 2016.
National Institute of Neurological
provisions set forth in sections David Clary,
Disorders and Stroke; Notice of Closed
Meeting 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Program Analyst, Office of Federal Advisory
as amended. The grant applications and Committee Policy.
Pursuant to section 10(d) of the the discussions could disclose [FR Doc. 2016–28901 Filed 12–1–16; 8:45 am]
Federal Advisory Committee Act, as confidential trade secrets or commercial BILLING CODE 4140–01–P
amended (5 U.S.C. App.), notice is property such as patentable material,
hereby given of the following meeting. and personal information concerning
The meeting will be closed to the individuals associated with the grant DEPARTMENT OF HEALTH AND
public in accordance with the applications, the disclosure of which HUMAN SERVICES
provisions set forth in sections would constitute a clearly unwarranted
552b(c)(4) and 552b(c)(6), Title 5 U.S.C., invasion of personal privacy. Substance Abuse and Mental Health
as amended. The grant applications and Services Administration
the discussions could disclose Name of Committee: National Institute of
confidential trade secrets or commercial Diabetes and Digestive and Kidney Diseases Current List of HHS-Certified
Special Emphasis Panel; Time-Sensitive Laboratories and Instrumented Initial
property such as patentable material, Obesity Applications.
and personal information concerning Testing Facilities Which Meet Minimum
Date: January 9, 2017.
individuals associated with the grant Time: 11:30 a.m. to 2:30 p.m. Standards To Engage in Urine Drug
applications, the disclosure of which Agenda: To review and evaluate grant Testing for Federal Agencies
would constitute a clearly unwarranted applications. AGENCY: Substance Abuse and Mental
invasion of personal privacy. Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy Health Services Administration, HHS.
Name of Committee: National Institute of Boulevard, Bethesda, MD 20892 (Telephone ACTION: Notice.
Neurological Disorders and Stroke Special Conference Call).
Emphasis Panel; Review of an IGNTE Contact Person: Michele L. Barnard, Ph.D., SUMMARY: The Department of Health and
Application. Scientific Review Officer, Review Branch, Human Services (HHS) notifies federal
Date: December 9, 2016. agencies of the laboratories and
DEA, NIDDK, National Institutes of Health,
Time: 11:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant
Room 7353, 6707 Democracy Boulevard, Instrumented Initial Testing Facilities
Bethesda, MD 20892–2542, (301) 594–8898, (IITF) currently certified to meet the
applications.
barnardm@extra.niddk.nih.gov. standards of the Mandatory Guidelines
Place: National Institutes of Health,
Name of Committee: National Institute of for Federal Workplace Drug Testing
asabaliauskas on DSK3SPTVN1PROD with NOTICES
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone Diabetes and Digestive and Kidney Diseases Programs (Mandatory Guidelines). The
Conference Call). Special Emphasis Panel; Clinical Studies in Mandatory Guidelines were first
Contact Person: Natalia Strunnikova, Kidney Transplant and Hemodialysis. published in the Federal Register on
Ph.D., Scientific Review Administrator, Date: February 2, 2017.
Time: 11:00 a.m. to 2:00 p.m.
April 11, 1988 (53 FR 11970), and
Scientific Review Branch, NINDS/NIH/
DHHS, Neuroscience Center, 6001 Executive Agenda: To review and evaluate grant subsequently revised in the Federal
Blvd., Suite 3204, MSC 9529, Bethesda, MD applications. Register on June 9, 1994 (59 FR 29908);
20892–9529, 301–496–9223, Place: National Institutes of Health, Two September 30, 1997 (62 FR 51118);
Natalia.strunnikova@nih.gov. Democracy Plaza, 6707 Democracy April 13, 2004 (69 FR 19644); November
VerDate Sep<11>2014 17:55 Dec 01, 2016 Jkt 241001 PO 00000 Frm 00031 Fmt 4703 Sfmt 4703 E:\FR\FM\02DEN1.SGM 02DEN1](https://thefederalregister.org/doc/81_FR_87279/page/1.svg)
![Federal Register / Vol. 81, No. 232 / Friday, December 2, 2016 / Notices 87049
800–729–6432 (Formerly: SmithKline DATES: Written comments should be comments will become a matter of
Beecham Clinical Laboratories; received on or before January 3, 2017 to public record. In this document, CBP is
SmithKline Bio-Science Laboratories) be assured of consideration. soliciting comments concerning the
Quest Diagnostics Incorporated, 400 ADDRESSES: Interested persons are following information collection:
Egypt Road, Norristown, PA 19403, invited to submit written comments on Title: Vessel Entrance or Clearance
610–631–4600/877–642–2216 this proposed information collection to Statement.
(Formerly: SmithKline Beecham the Office of Information and Regulatory OMB Number: 1651–0019.
Clinical Laboratories; SmithKline Bio- Affairs, Office of Management and Form Number: CBP Form 1300.
Science Laboratories) Budget. Comments should be addressed Abstract: CBP Form 1300, Vessel
Quest Diagnostics Incorporated, 8401 to the OMB Desk Officer for Customs Entrance or Clearance Statement, is
Fallbrook Ave., West Hills, CA 91304, and Border Protection, Department of used to collect essential commercial
818–737–6370 (Formerly: SmithKline Homeland Security, and sent via vessel data at time of formal entrance
Beecham Clinical Laboratories) electronic mail to oira_submission@ and clearance in U.S. ports. The form
Redwood Toxicology Laboratory, 3700 omb.eop.gov or faxed to (202) 395–5806. allows the master to attest to the
Westwind Blvd., Santa Rosa, CA truthfulness of all CBP forms associated
FOR FURTHER INFORMATION CONTACT:
95403, 800–255–2159 with the manifest package, and collects
Requests for additional information information about the vessel, cargo,
Southwest Laboratories, 4625 E. Cotton should be directed to Paperwork purpose of entrance, certificate
Center Boulevard, Suite 177, Phoenix, Reduction Act Officer, U.S. Customs numbers, and expiration for various
AZ 85040, 602–438–8507/800–279– and Border Protection, Regulations and certificates. It also serves as a record of
0027 Rulings, Office of Trade, 90 K Street fees and tonnage tax payments in order
STERLING Reference Laboratories, 2617 NE., 10th Floor, Washington, DC 20229– to prevent overpayments. CBP Form
East L Street, Tacoma, Washington 1177, or via email (CBP_PRA@ 1300 was developed through agreement
98421, 800–442–0438 cbp.dhs.gov). Please note contact by the United Nations
US Army Forensic Toxicology Drug information provided here is solely for Intergovernmental Maritime
Testing Laboratory, 2490 Wilson St., questions regarding this notice. Consultative Organization (IMCO) in
Fort George G. Meade, MD 20755– Individuals seeking information about conjunction with the United States and
5235, 301–677–7085, Testing for other CBP programs please contact the various other countries. This form is
Department of Defense (DoD) CBP National Customer Service Center authorized by 19 U.S.C. 1431, 1433, and
Employees Only at 877–227–5511, (TTY) 1–800–877– 1434, and provided for by 19 CFR 4.7–
Charles LoDico,
8339, or CBP Web site at https:// 4.9, and accessible at http://
www.cbp.gov/. For additional help: www.cbp.gov/newsroom/publications/
Chemist.
https://help.cbp.gov/app/home/ forms?title=1300.
[FR Doc. 2016–28940 Filed 12–1–16; 8:45 am]
search/1. Current Actions: CBP proposes to
BILLING CODE 4160–20–P
SUPPLEMENTARY INFORMATION: This extend the expiration date of this
proposed information collection was information collection with no change
previously published in the Federal to the burden hours or to the
DEPARTMENT OF HOMELAND Register (81 FR 62517) on September 9, information being collected.
SECURITY 2016, allowing for a 60-day comment Type of Review: Extension (without
period. This notice allows for an change).
U.S. Customs and Border Protection additional 30 days for public comments. Affected Public: Businesses.
This process is conducted in accordance Estimated Number of Respondents:
[1651–0019] with 5 CFR 1320.10. CBP invites the 12,000.
general public and other Federal Estimated Number of Responses per
Agency Information Collection Respondent: 22.
agencies to comment on proposed and/
Activities: Vessel Entrance or Estimated Total Annual Responses:
or continuing information collections
Clearance Statement 264,000.
pursuant to the Paperwork Reduction
AGENCY: U.S. Customs and Border Act of 1995 (44 U.S.C. 3507). The Estimated Time per Response: 30
Protection, Department of Homeland comments should address: (a) Whether minutes.
Security. the collection of information is Estimated Total Annual Burden
necessary for the proper performance of Hours: 132,000.
ACTION: 30-Day notice and request for
comments; Extension of an existing the functions of the agency, including Dated: November 28, 2016.
collection of information. whether the information shall have Seth Renkema,
practical utility; (b) the accuracy of the Branch Chief, Economic Impact Analysis
SUMMARY: U.S. Customs and Border agency’s estimates of the burden of the Branch, U.S. Customs and Border Protection.
Protection (CBP) of the Department of collection of information; (c) ways to [FR Doc. 2016–28923 Filed 12–1–16; 8:45 am]
Homeland Security will be submitting enhance the quality, utility, and clarity BILLING CODE 9111–14–P
the following information collection of the information to be collected; (d)
request to the Office of Management and ways to minimize the burden, including
Budget (OMB) for review and approval the use of automated collection DEPARTMENT OF HOUSING AND
in accordance with the Paperwork techniques or the use of other forms of
asabaliauskas on DSK3SPTVN1PROD with NOTICES
URBAN DEVELOPMENT
Reduction Act: Vessel of Entrance or information technology; and (e) the
Clearance Statement (CBP Form 1300). annual costs to respondents or record [Docket No. FR–5907–N–49]
CBP is proposing that this information keepers from the collection of
Federal Property Suitable as Facilities
collection be extended with no change information (total capital/startup costs
To Assist the Homeless
to the burden hours or to the and operations and maintenance costs).
information collected. This document is The comments that are submitted will AGENCY: Office of the Assistant
published to obtain comments from the be summarized and included in the CBP Secretary for Community Planning and
public and affected agencies. request for OMB approval. All Development, HUD.
VerDate Sep<11>2014 17:55 Dec 01, 2016 Jkt 241001 PO 00000 Frm 00033 Fmt 4703 Sfmt 4703 E:\FR\FM\02DEN1.SGM 02DEN1](https://thefederalregister.org/doc/81_FR_87279/page/3.svg)
Document Created: 2018-02-14 09:02:23
Document Modified: 2018-02-14 09:02:23
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| Action | Notice. | |
| Contact | Giselle Hersh, Division of Workplace Programs, SAMHSA/CSAP, 5600 Fishers Lane, Room 16N03A, Rockville, Maryland 20857; 240-276-2600 (voice). | |
| FR Citation | 81 FR 87047 |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR